Picture of BridgeBio Pharma logo

BBIO BridgeBio Pharma Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapMomentum Trap

Annual income statement for BridgeBio Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue40.68.2569.777.69.3
Cost of Revenue
Gross Profit38.18.2566.674.26.86
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses307483646590617
Operating Profit-267-474-577-512-607
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-289-505-586-485-653
Net Income After Taxes-289-505-586-485-653
Minority Interest
Net Income Before Extraordinary Items
Net Income-261-449-563-481-643
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-261-449-563-481-643
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-2.46-3.8-3.9-2.97-3.9